<turbo-stream action="append" target="news"><template>  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-secondary bg-gray-200">
          Neutral
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/en/stock/uniQure-N-V-NL0010696654">uniQure N.V.</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">GlobeNewsWire</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">6 months ago</div>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://www.globenewswire.com/news-release/2026/04/02/3267839/32716/en/QURE-SHAREHOLDER-ALERT-Hagens-Berman-Updates-uniQure-QURE-Investigation-Following-Public-FDA-Rebukes-and-Allegations-of-Distorted-Data.html">QURE SHAREHOLDER ALERT: Hagens Berman Updates uniQure (QURE) Investigation Following Public FDA Rebukes and Allegations of “Distorted” Data</a>
    </div>

      <div class="me-0 me-md-5">
        SAN FRANCISCO, April 02, 2026 (GLOBE NEWSWIRE) -- National shareholder rights law firm Hagens Berman is updating its investigation into uniQure N.V. (NASDAQ: QURE) a series of extraordinary rebukes by Food and Drug Administration (FDA) officials.
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-secondary bg-gray-200">
          Neutral
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/en/stock/uniQure-N-V-NL0010696654">uniQure N.V.</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">PRNewsWire</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">6 months ago</div>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://www.prnewswire.com/news-releases/qure-deadline-qure-investors-have-opportunity-to-lead-uniqure-nv-securities-fraud-lawsuit-302732039.html">QURE Deadline: QURE Investors Have Opportunity to Lead uniQure N.V. Securities Fraud Lawsuit</a>
    </div>

      <div class="me-0 me-md-5">
        NEW YORK, April 1, 2026 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of ordinary shares of uniQure N.V. (NASDAQ: QURE) between September 24, 2025, and October 31, 2025, inclusive (the &quot;Class Period&quot;), of the important April 13, 2026 lead plaintiff deadline.
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-secondary bg-gray-200">
          Neutral
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/en/stock/uniQure-N-V-NL0010696654">uniQure N.V.</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">PRNewsWire</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">6 months ago</div>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://www.prnewswire.com/news-releases/qure-alert-hagens-berman-updates-uniqure-qure-probe-after-fda-criticism-april-13-deadline-nears-302731828.html">QURE ALERT: Hagens Berman Updates uniQure (QURE) Probe After FDA Criticism; April 13 Deadline Nears</a>
    </div>

      <div class="me-0 me-md-5">
        SAN FRANCISCO, April 1, 2026 /PRNewswire/ -- National shareholder rights law firm Hagens Berman is updating its investigation into uniQure N.V. (NASDAQ: QURE) a series of extraordinary rebukes by Food and Drug Administration (FDA) officials.
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-secondary bg-gray-200">
          Neutral
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/en/stock/uniQure-N-V-NL0010696654">uniQure N.V.</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">PRNewsWire</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">6 months ago</div>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://www.prnewswire.com/news-releases/qure-shareholder-notice-hagens-berman-updates-uniqure-qure-investigation-following-public-fda-rebukes-and-allegations-of-distorted-data-302729028.html">QURE SHAREHOLDER NOTICE: Hagens Berman Updates uniQure (QURE) Investigation Following Public FDA Rebukes and Allegations of &quot;Distorted&quot; Data</a>
    </div>

      <div class="me-0 me-md-5">
        Firm Reminds Investors of April 13 Lead Plaintiff Deadline in Pending Suit SAN FRANCISCO, March 30, 2026 /PRNewswire/ -- National shareholder rights law firm Hagens Berman is updating its investigation into uniQure N.V. (NASDAQ: QURE) a series of extraordinary rebukes by Food and Drug Administration (FDA) officials.
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-secondary bg-gray-200">
          Neutral
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/en/stock/uniQure-N-V-NL0010696654">uniQure N.V.</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">PRNewsWire</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">6 months ago</div>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://www.prnewswire.com/news-releases/uniqure-nv-sued-for-securities-law-violations---contact-the-djs-law-group-to-discuss-your-rights--qure-302728378.html">uniQure N.V. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - QURE</a>
    </div>

      <div class="me-0 me-md-5">
        LOS ANGELES, March 30, 2026 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against uniQure N.V. (&quot;uniQure&quot; or &quot;the Company&quot;) (NASDAQ: QURE) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

</template></turbo-stream><turbo-stream action="replace" target="link"><template><div id="link">
    <a class="btn btn-outline-primary btn--small" data-turbo-stream="" href="/en/news/uniQure-N-V-NL0010696654/load_more?page=6">
      Show more News
      <i class="fa fa-arrow-down fa-fw"></i>
</a></div>
</template></turbo-stream>